Myriad Genetics, Inc. – NASDAQ:MYGN
Myriad Genetics stock price today
$5.579
-7.84
-58.43%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 2 hours
Myriad Genetics stock price monthly change
-49.20%
month
Myriad Genetics stock price quarterly change
-49.20%
quarter
Myriad Genetics stock price yearly change
-32.15%
year
Myriad Genetics key metrics
Market Cap | 1.22B |
Enterprise value | 1.96B |
P/E | -16.42 |
EV/Sales | 2.89 |
EV/EBITDA | -23.16 |
Price/Sales | 2.76 |
Price/Book | 2.11 |
PEG ratio | 0.05 |
EPS | -3.36 |
Revenue | 734.4M |
EBITDA | -212.4M |
Income | -274.4M |
Revenue Q/Q | 22.69% |
Revenue Y/Y | 11.03% |
Profit margin | -16.51% |
Oper. margin | -19.15% |
Gross margin | 70.22% |
EBIT margin | -19.15% |
EBITDA margin | -28.92% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMyriad Genetics stock price history
Myriad Genetics stock forecast
Myriad Genetics financial statements
Average Price Target
$30.2
Potential upside: 441.31%
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 177.8M | -42.3M | -23.79% |
|---|---|---|---|
| Mar 2023 | 181.2M | -54.7M | -30.19% |
| Jun 2023 | 183.5M | -116.1M | -63.27% |
| Sep 2023 | 191.9M | -61.3M | -31.94% |
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2020 | 40.79% |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 |
| Dec 2022 | 1198700000 | 312.9M | 26.1% |
|---|---|---|---|
| Mar 2023 | 1169300000 | 334.1M | 28.57% |
| Jun 2023 | 1187200000 | 452M | 38.07% |
| Sep 2023 | 1149100000 | 465.7M | 40.53% |
| Dec 2022 | -7.7M | -35.6M | -2.1M |
|---|---|---|---|
| Mar 2023 | -33.2M | 34.6M | -4.9M |
| Jun 2023 | -900K | 11.8M | 38.4M |
| Sep 2023 | -22.1M | -2.5M | -2.5M |
Myriad Genetics alternative data
| Sep 2023 | 2,600 |
|---|---|
| Oct 2023 | 2,600 |
| Nov 2023 | 2,600 |
| Dec 2023 | 2,600 |
| Jan 2024 | 2,600 |
| Feb 2024 | 2,600 |
| Mar 2024 | 2,700 |
| Apr 2024 | 2,700 |
| May 2024 | 2,700 |
| Jun 2024 | 2,700 |
| Jul 2024 | 2,700 |
Myriad Genetics other data
90.02%
-9.93%
of MYGN is owned by hedge funds
167
-25
72.37M
-7.68M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 30000 |
| May 2024 | 0 | 234044 |
| Jun 2024 | 0 | 7576 |
| Aug 2024 | 0 | 19038 |
| Sep 2024 | 0 | 73112 |
| Oct 2024 | 0 | 15000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | DIAZ PAUL J director, officer.. | Common Stock | 15,000 | $22.93 | $343,950 | ||
Sale | DIAZ PAUL J director, officer.. | Common Stock | 15,000 | $22.93 | $343,950 | ||
Sale | DIAZ PAUL J director, officer.. | Common Stock | 15,000 | $26.72 | $400,800 | ||
Sale | DIAZ PAUL J director, officer.. | Common Stock | 15,000 | $26.72 | $400,800 | ||
Sale | MUZZEY DALE officer: Chief Scientific Officer | Common Stock | 2,100 | $26.17 | $54,961 | ||
Sale | DREISMANN HEINRICH director | Common Stock | 10,000 | $27.05 | $270,520 | ||
Sale | REITAN COLLEEN F director | Common Stock | 46,012 | $27.95 | $1,285,851 | ||
Sale | ANCONA MARGARET officer: SVP, Chief of Staff | Common Stock | 11,538 | $27.82 | $320,987 | ||
Sale | KUMAR RASHMI director | Common Stock | 7,500 | $28.01 | $210,075 | ||
Sale | SPIEGELMAN DANIEL K director | Common Stock | 3,788 | $22.05 | $83,525 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Paul J. Diaz (1962) Chief Executive Officer, Pres & Director | $1,990,000 |
Mr. R. Bryan Riggsbee (1971) Executive Vice President, Chief Financial Officer & Treasurer | $741,840 |
| Dr. Jerry S. Lanchbury Ph.D. (1959) Chief Scientific Officer | $632,040 |
| Mr. Mark S. Verratti (1968) Pres of Myriad Neuroscience & Autoimmune | $560,700 |
| Ms. Nicole Lambert (1974) Chief Operating Officer | $507,510 |
Myriad Genetics: Significantly Undervalued With Profitability In Sight
Myriad Genetics' Strategic Growth Fuels Bullish Outlook
Myriad Genetics: FRα Addition Further Diversifies Portfolio
Illumina Engages Obama To Push Its Customers' Reimbursement Agenda
Invitae Busted Business Model Offers A Tactical Opportunity
Myriad Genetics, Inc. 2022 Q2 - Results - Earnings Call Presentation
Veracyte: Fading The Rally
Myriad Genetics, Inc. 2022 Q1 - Results - Earnings Call Presentation
-
What's the price of Myriad Genetics stock today?
One share of Myriad Genetics stock can currently be purchased for approximately $5.58.
-
When is Myriad Genetics's next earnings date?
Unfortunately, Myriad Genetics's (MYGN) next earnings date is currently unknown.
-
Does Myriad Genetics pay dividends?
No, Myriad Genetics does not pay dividends.
-
How much money does Myriad Genetics make?
Myriad Genetics has a market capitalization of 1.22B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 11.03% to 753.2M US dollars.
-
What is Myriad Genetics's stock symbol?
Myriad Genetics, Inc. is traded on the NASDAQ under the ticker symbol "MYGN".
-
What is Myriad Genetics's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Myriad Genetics?
Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Myriad Genetics's key executives?
Myriad Genetics's management team includes the following people:
- Mr. Paul J. Diaz Chief Executive Officer, Pres & Director(age: 63, pay: $1,990,000)
- Mr. R. Bryan Riggsbee Executive Vice President, Chief Financial Officer & Treasurer(age: 54, pay: $741,840)
- Dr. Jerry S. Lanchbury Ph.D. Chief Scientific Officer(age: 66, pay: $632,040)
- Mr. Mark S. Verratti Pres of Myriad Neuroscience & Autoimmune(age: 57, pay: $560,700)
- Ms. Nicole Lambert Chief Operating Officer(age: 51, pay: $507,510)
-
How many employees does Myriad Genetics have?
As Jul 2024, Myriad Genetics employs 2,700 workers.
-
When Myriad Genetics went public?
Myriad Genetics, Inc. is publicly traded company for more then 29 years since IPO on 6 Oct 1995.
-
What is Myriad Genetics's official website?
The official website for Myriad Genetics is myriad.com.
-
Where are Myriad Genetics's headquarters?
Myriad Genetics is headquartered at 320 Wakara Way, Salt Lake City, UT.
-
How can i contact Myriad Genetics?
Myriad Genetics's mailing address is 320 Wakara Way, Salt Lake City, UT and company can be reached via phone at 801 584 3600.
-
What is Myriad Genetics stock forecast & price target?
Based on 5 Wall Street analysts` predicted price targets for Myriad Genetics in the last 12 months, the avarage price target is $30.2. The average price target represents a 441.31% change from the last price of $5.58.
Myriad Genetics company profile:
Myriad Genetics, Inc.
myriad.comExchange:
NASDAQ
Full time employees:
2,700
Industry:
Medical - Diagnostics & Research
Sector:
Healthcare
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
320 Wakara Way
Salt Lake City, UT 84108
Salt Lake City, UT 84108
CIK: 0000899923
ISIN: US62855J1043
CUSIP: 62855J104
